{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T05:57:42Z","timestamp":1788587862735,"version":"build-2803163510"},"reference-count":49,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1097\/mjt.0b013e318217a5d1","type":"journal-article","created":{"date-parts":[[2011,6,3]],"date-time":"2011-06-03T16:06:53Z","timestamp":1307117213000},"page":"676-684","source":"Crossref","is-referenced-by-count":4,"title":["Implications of Over-the-Counter Proton Pump Inhibitors for Patient Counseling by Pharmacists"],"prefix":"10.1097","volume":"20","author":[{"given":"William","family":"Simonson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-13-20210202","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1111\/j.1572-0241.2006.00630.x","article-title":". The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus.","volume":"101","author":"Vakil","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"R2-13-20210202","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.gtc.2007.07.014","article-title":"The many manifestations of gastroesophageal reflux disease: presentation, evaluation, and treatment.","volume":"36","author":"Richter","year":"2007","journal-title":"Gastroenterol Clin North Am"},{"key":"R3-13-20210202","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1080\/003655298750026697","article-title":". The usefulness of a structured questionnaire in the assessment of symptomatic gastroesophageal reflux disease.","volume":"33","author":"Carlsson","year":"1998","journal-title":"Scand J Gastroenterol"},{"key":"R4-13-20210202","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/j.1365-2710.2004.00620.x","article-title":". Comparison of Prilosec OTC (omeprazole magnesium 20.6 mg) to placebo for 14 days in the treatment of frequent heartburn.","volume":"30","author":"Allgood","year":"2005","journal-title":"J Clin Pharm Ther"},{"key":"R5-13-20210202","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1365-2036.2006.03129.x","article-title":"Comparison of gastric pH with omeprazole magnesium 20.6 mg (Prilosec OTC) o.m. famotidine 10 mg (Pepcid AC) b.d. and famotidine 20 mg b.d. over 14 days of treatment.","volume":"25","author":"Miner","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"R6-13-20210202","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1053\/j.gastro.2008.08.044","article-title":"American Gastroenterological Association Institute technical review on the management of gastroesophageal reflux disease.","volume":"135","author":"Kahrilas","year":"2008","journal-title":"Gastroenterology"},{"key":"R7-13-20210202","first-page":"701","article-title":"Approach to gastroesophageal reflux disease in primary care: putting the Montreal definition into practice.","volume":"54","author":"Flook","year":"2008","journal-title":"Can Fam Physician"},{"key":"R8-13-20210202","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1053\/j.gastro.2008.08.045","article-title":". American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease.","volume":"135","author":"Kahrilas","year":"2008","journal-title":"Gastroenterology"},{"key":"R9-13-20210202","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S1542-3565(05)00153-9","article-title":". Prevalence and socioeconomic impact of upper gastrointestinal disorders in the United States: results of the US Upper Gastrointestinal Study.","volume":"3","author":"Camilleri","year":"2005","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R11-13-20210202","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1001\/archinte.159.14.1592","article-title":". Heartburn risk factors, knowledge, and prevention strategies: a population-based survey of individuals with heartburn.","volume":"159","author":"Oliveria","year":"1999","journal-title":"Arch Intern Med"},{"key":"R12-13-20210202","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1097\/MEG.0b013e3282c3a967","article-title":"Cancer risk in Barretts oesophagus.","volume":"19","author":"Dias","year":"2007","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R14-13-20210202","first-page":"483","article-title":". Atypical presentations of gastroesophageal reflux disease.","volume":"78","author":"Heidelbaugh","year":"2008","journal-title":"Am Fam Physician"},{"key":"R15-13-20210202","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1097\/00005650-199211000-00003","article-title":". The effects of consultation on over-the-counter medication purchasing decisions.","volume":"30","author":"Nichol","year":"1992","journal-title":"Med Care"},{"key":"R16-13-20210202","doi-asserted-by":"crossref","first-page":"499","DOI":"10.18553\/jmcp.2002.8.6.499","article-title":"Analysis of the movement of prescription drugs to over-the-counter status.","volume":"8","author":"Harrington","year":"2002","journal-title":"J Manag Care Pharm"},{"key":"R17-13-20210202","first-page":"2209","article-title":"Prescription to over-the-counter drug reclassification.","volume":"57","author":"Jacobs","year":"1998","journal-title":"Am Fam Physician"},{"key":"R19-13-20210202","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1023\/A:1016334411840","article-title":"Factors related to pharmacists over-the-counter recommendations.","volume":"27","author":"Kotecki","year":"2002","journal-title":"J Community Health"},{"key":"R20-13-20210202","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S1542-3565(03)00287-8","article-title":". Self-selection and use patterns of over-the-counter omeprazole for frequent heartburn.","volume":"2","author":"Fendrick","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R21-13-20210202","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1023\/A:1008733207854","article-title":"Evaluation of the impact of pharmacists advice giving on the outcomes of self-medication in patients suffering from dyspepsia.","volume":"22","author":"Krishnan","year":"2000","journal-title":"Pharm World Sci"},{"key":"R22-13-20210202","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S1086-5802(16)31123-8","article-title":"Patient-guided counseling in the community pharmacy setting.","volume":"40","author":"Barnett","year":"2000","journal-title":"J Am Pharm Assoc (Wash)"},{"key":"R23-13-20210202","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1331\/154434506775268724","article-title":"Achieving patient centeredness in pharmacy practice: openness and the pharmacists natural attitude.","volume":"46","author":"de Oliveira","year":"2006","journal-title":"J Am Pharm Assoc"},{"key":"R24-13-20210202","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1331\/154434504322713192","article-title":"Patient counseling provided in community pharmacies: effects of state regulation, pharmacist age, and busyness.","volume":"44","author":"Svarstad","year":"2004","journal-title":"J Am Pharm Assoc"},{"key":"R25-13-20210202","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0160-3450(15)30660-7","article-title":"Active listening: a key to effective communication.","volume":"NS33","author":"Srnka","year":"1993","journal-title":"Am Pharm"},{"key":"R26-13-20210202","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1007\/s11096-005-4798-7","article-title":"Treatment of gastroesophageal reflux disease.","volume":"27","author":"Pettit","year":"2005","journal-title":"Pharm World Sci"},{"key":"R27-13-20210202","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1053\/bega.2001.0184","article-title":"Pharmacological and pharmacodynamic essentials of H(2)-receptor antagonists and proton pump inhibitors for the practicing physician.","volume":"15","author":"Huang","year":"2001","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"R28-13-20210202","first-page":"CD00","article-title":". Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease.","volume":"3","author":"van Pinxteren","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"R29-13-20210202","doi-asserted-by":"crossref","first-page":"855","DOI":"10.2165\/00003495-199957060-00003","article-title":"Antacids revisited: a review of their clinical pharmacology and recommended therapeutic use.","volume":"57","author":"Maton","year":"1999","journal-title":"Drugs"},{"key":"R30-13-20210202","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1111\/j.1440-1746.2006.04323.x","article-title":". Tolerance to H2 receptor antagonist correlates well with the decline in efficacy against gastroesophageal reflux in patients with gastroesophageal reflux disease.","volume":"21","author":"Furuta","year":"2006","journal-title":"J Gastroenterol Hepatol"},{"key":"R31-13-20210202","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1053\/gast.2002.31876","article-title":". Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough.","volume":"122","author":"Fackler","year":"2002","journal-title":"Gastroenterology"},{"key":"R32-13-20210202","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2165\/00002512-199609040-00003","article-title":"Treatment of peptic ulcer in the elderly. Proton pump inhibitors and histamine H2 receptor antagonists.","volume":"9","author":"Lazzaroni","year":"1996","journal-title":"Drugs Aging"},{"key":"R33-13-20210202","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.jacc.2007.07.090","article-title":"Omeprazole: a possible new candidate influencing the antiplatelet effect of clopidogrel.","volume":"51","author":"Gurbel","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"R34-13-20210202","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S0140-6736(09)61525-7","article-title":". Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials.","volume":"374","author":"ODonoghue","year":"2009","journal-title":"Lancet"},{"key":"R35-13-20210202","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/j.1365-2036.2005.02654.x","article-title":"The management of heartburn in pregnancy review article.","volume":"22","author":"Richter","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"R36-13-20210202","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2165\/00003088-200039040-00005","article-title":"Selection of drugs to treat gastro-oesophageal reflux disease: the role of drug interactions.","volume":"39","author":"Flockhart","year":"2000","journal-title":"Clin Pharmacokinet"},{"key":"R40-13-20210202","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0022-510X(98)00307-4","article-title":"Pramipexolea new dopamine agonist for the treatment of Parkinsons disease.","volume":"163","author":"Bennett","year":"1999","journal-title":"J Neurol Sci"},{"key":"R42-13-20210202","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1046\/j.1365-2036.2000.00788.x","article-title":"Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors.","volume":"14","author":"Stedman","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"R43-13-20210202","doi-asserted-by":"crossref","first-page":"911","DOI":"10.2165\/00002512-200219120-00003","article-title":"Treatment of acid-related diseases in the elderly with emphasis on the use of proton pump inhibitors.","volume":"19","author":"Thjodleifsson","year":"2002","journal-title":"Drugs Aging"},{"key":"R44-13-20210202","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1001\/jama.296.24.2947","article-title":". Long-term proton pump inhibitor therapy and risk of hip fracture.","volume":"296","author":"Yang","year":"2006","journal-title":"JAMA"},{"key":"R45-13-20210202","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s11894-010-0103-6","article-title":"Safety of proton pump inhibitors: current evidence for osteoporosis and interaction with antiplatelet agents.","volume":"12","author":"Johnson","year":"2010","journal-title":"Curr Gastroenterol Rep"},{"key":"R48-13-20210202","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jacc.2007.06.064","article-title":". Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study.","volume":"51","author":"Gilard","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"R49-13-20210202","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.jacc.2008.05.053","article-title":"Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors.","volume":"52","author":"Pezalla","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"R50-13-20210202","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1345\/aph.1M051","article-title":"Drug-drug interaction between clopidogrel and the proton pump inhibitors.","volume":"43","author":"Norgard","year":"2009","journal-title":"Ann Pharmacother"},{"key":"R51-13-20210202","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1177\/0091270008315310","article-title":". Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel.","volume":"48","author":"Small","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"R52-13-20210202","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1365-2036.2007.03381.x","article-title":". Systematic review: maintenance treatment of gastro-oesophageal reflux disease with proton pump inhibitors taken on-demand.","volume":"26","author":"Pace","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"R53-13-20210202","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1155\/2007\/203201","article-title":". Maintenance treatment of gastroesophageal reflux disease: an evaluation of continuous and on-demand therapy with rabeprazole 20 mg.","volume":"21","author":"Morgan","year":"2007","journal-title":"Can J Gastroenterol"},{"key":"R54-13-20210202","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3810\/pgm.2009.07.2019","article-title":". Lansoprazole 15 mg once daily for 14 days is effective for treatment of frequent heartburn: results of 2 randomized, placebo-controlled, double-blind studies.","volume":"121","author":"Kushner","year":"2009","journal-title":"Postgrad Med"},{"key":"R55-13-20210202","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/j.1365-2036.2009.04064.x","article-title":". Clinical trial: lansoprazole 15 or 30 mg once daily vs placebo for treatment of frequent nighttime heartburn in self-treating subjects.","volume":"30","author":"Peura","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"R56-13-20210202","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2165\/00003088-199631010-00002","article-title":"Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole.","volume":"31","author":"Andersson","year":"1996","journal-title":"Clin Pharmacokinet"},{"key":"R57-13-20210202","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1093\/ajhp\/53.12.1401","article-title":"Lansoprazole and omeprazole in the treatment of acid peptic disorders.","volume":"53","author":"Blum","year":"1996","journal-title":"Am J Health Syst Pharm"},{"key":"R58-13-20210202","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/j.1875-9114.1997.tb03714.x","article-title":"Lansoprazole: a comprehensive review.","volume":"17","author":"Zimmermann","year":"1997","journal-title":"Pharmacotherapy"}],"container-title":["American Journal of Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MJT.0b013e318217a5d1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,7]],"date-time":"2024-04-07T09:06:11Z","timestamp":1712480771000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00045391-201311000-00013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/mjt.0b013e318217a5d1","relation":{},"ISSN":["1075-2765"],"issn-type":[{"value":"1075-2765","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]}}}